TRK-A, HER-2/neu, and KIT expression/activation profiles in salivary gland carcinoma

Translational Oncology

Volumn 1, Issue 3, 2008, Pages 121-128

  Negri, Tiziana ^a   Tamborini, Elena ^a   Dagrada, Gian Paolo ^a   Greco, Angela ^a   Staurengo, Samantha ^a   Guzzo, Marco ^a   Locati, Laura D ^a   Carbone, Antonino ^a   Pierotti, Marco A ^a   Licitra, Lisa ^a   Pilotti, Silvana ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70349922682     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.08127     Document Type: Article

References (47)

1. Guzzo M, Di Palma S, Grandi C, and Molinari R (1997). Salivary duct carcinoma: clinical characteristics and treatment strategies. Head Neck 19, 126-133.
2. De Vicente JC, Garcia-Suarez O, Esteban I, Santamaria J, and Vega JA (1998). Immunohistochemical localization of neurotrophins and neurotrophin receptors in human and mouse salivary glands. Ann Anat 180, 157-163.
3. Jeng YM, Lin CY, and Hsu HC (2000). Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett 154, 107-111.
4. Freier K, Flechtenmacher C, Walch A, Devens F, Mühling J, Lichter P, Joos S, and Hofele C (2005). Differential KIT expression in histological subtypes of adenoid cystic carcinoma (ACC) of the salivary gland. Oral Oncol 41, 934-939.
5. Seethala RR, Hunt JL, Baloch ZW, Livolsi VA, and Leon Barnes E (2007). Adenoid cystic carcinoma with high-grade transformation: a report of 11 cases and a review of the literature. Am J Surg Pathol 31, 1683-1694.
6. Press MF, Pike MC, Hung G, Zhou JY, Ma Y, George J, Dietz-Band J, James W, Slamon DJ, and Batsakis JG (1994). Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 54, 5675-5682.
7. Skalova A, Starek I, Vanecek T, Kucerova V, Plank L, Szepe P, Di Palma S, and Leivo I (2003). Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology 42, 348-356.
8. Dagrada GP, Negri T, Tamborini E, Pierotti MA, and Pilotti S (2004). Re: Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology 44, 301-302.
9. Dolle L, El Yazidi-Belkoura I, Adriaenssens E, Nurcombe V, and Hondermarck H (2003). Nerve growth factor overexpression and autocrine loop in breast cancer cells. Oncogene 22, 5592-5601.
10. Wang L, Sun M, Jiang Y, Yang L, Lei D, Lu C, Zhao Y, Zhang P, Yang Y, and Li J (2006). Nerve growth factor and tyrosine kinase A in human salivary adenoid cystic carcinoma: expression patterns and effects on in vitro invasive behaviour. J Oral Maxillofac Surg 64, 636-641.
11. Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff N, Vaught JL, Murakata C, Djakiew D, Lamb J, Bova S, et al. (1998). Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res 4, 1887-1898.
12. Weeraratna AT, Arnold JT, George DJ, DeMarzo A, and Isaacs JT (2000). Rational basis for Trk inhibition therapy for prostate cancer. Prostate 45, 140-148.
13. Miknyoczki SJ, Lang D, Huang L, Klein-Szanto AJ, Dionne CA, and Ruggeri BA (1999). Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: expression patterns and effects on in vitro invasive behaviour. Int J Cancer 81, 417-427.
14. Sakamoto Y, Kitajima Y, Edakuni G, Sasatomi E, Mori M, Kitahara K, and Miyazaki K (2001). Expression of Trk tyrosine kinase receptor is a biologic marker for cell proliferation and perineural invasion of human pancreatic ductal adenocarcinoma. Oncol Rep 8, 477-484.
15. Weeraratna AT, Dalrymple SL, Lamb JC, Denmeade SR, Miknyoczki S, Dionne CA, and Isaacs JT (2001). Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. Clin Cancer Res 7, 2237-2245.
16. Beckhardt S (2004). Re: growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy. J Urol 172, 1545.
17. Marshall JL, Kindler H, Deeken J, Bhargava P, Vogelzang NJ, Rizvi N, Luhtala T, Boylan S, Dordal M, Robertson P, et al. (2005). Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs 23, 31-37.
18. Felix A, El-Naggar AK, Press MF, Ordonez NG, Fonseca I, Tucker SL, Luna MA, and Batsakis JG (1996). Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum Pathol 27, 561-566.
19. Glisson B, Colevas AD, Haddad R, Krane J, El-Naggar A, Kies M, Costello R, Summey C, Arquette M, Langer C, et al. (2004). HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res 10, 944-946.
20. Skalova A, Starek I, Kucerova V, Szepe P, and Plank L (2001). Salivary duct carcinoma-a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. Pathol Res Pract 197, 621-626.
21. Martinez-Barba E, Cortes-Guardiola JA, Minguela-Puras A, Torroba-Caron A, Mendez-Trujillo S, and Bermejo-Lopez J (1997). Salivary duct carcinoma: clinicopathological and immunohistochemical studies. J Craniomaxillofac Surg 25, 328-334.
22. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, and McGuire WL (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182.
23. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, and Leahy DJ (2003). Structure of the extracellular region of HER2 alone and in complex with the herceptin Fab. Nature 421, 756-760.
24. Leyland-Jones B (2002). Trastuzumab: hopes and realities. Lancet Oncol 3, 137-144.
25. Lammie A, Drobnjak M, Gerald W, Saad A, Cote R, and Cordon-Cardo C (1994). Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem 42, 1417-1425.
26. Sato K, Shimode Y, Itoi A, Ueda Y, and Katsuda S (2007). Salivary duct carcinoma of the parotid gland presenting KIT (CD117) overexpression. Histopathology 51, 114-115.
27. Heinrich MC, Rubin BP, Longley BJ, and Fletcher JA (2002). Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 33, 484-495.
28. Holst VA, Marshall CE, Moskaluk CA, and Frierson HF Jr (1999). KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 12, 956-960.
29. Martin-Zanca D, Oskam R, Mitra G, Copeland T, and Barbacid M (1989). Molecular and biochemical characterization of the human trk proto-oncogene. Mol Cell Biol 9, 24-33.
30. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, Bertulli R, Colecchia M, Casali PG, Pierotti MA, et al. (2004). A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127, 294-299.
31. Tamborini E, Bonadiman L, Greco A, Gronchi A, Riva C, Bertulli R, Casali PG, Pierotti MA, and Pilotti S (2004). Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma. Clin Cancer Res 10, 938-943.
32. Tagliabue E, Ghirelli C, Lombardi L, Castiglioni F, Asnaghi L, Longhi C, Borrello MG, Aiello P, and Menard S (1999). Production of a monoclonal antibody directed against the high-affinity nerve growth factor receptor. Int J Biol Markers 14, 68-72.
33. INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Clin Cancer Res 9, 4132-4138.
34. Dagrada GP, Mezzelani A, Alasio L, Ruggeri M, Romano R, Pierotti MA, and Pilotti S (2003). HER-2/neu assessment in primary chemotherapy treated breast carcinoma: no evidence of gene profile changing. Breast Cancer Res Treat 80, 207-214.
35. Tamborini E, Bonadiman L, Negri T, Greco A, Staurengo S, Bidoli P, Pastorino U, Pierotti MA, and Pilotti S (2004). Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer. Clin Cancer Res 10, 8214-8219.
36. Tagliabue E, Castiglioni F, Ghirelli C, Modugno M, Asnaghi L, Somenzi G, Melani C, and Menard S (2000). Nerve growth factor cooperates with p185 (HER2) in activating growth of human breast carcinoma cells. J Biol Chem 275, 5388-5394.
37. George DJ, Suzuki H, Bova GS, and Isaacs JT (1998). Mutational analysis of the TrkA gene in prostate cancer. Prostate 36, 172-180.
38. Pierotti MA and Greco A (2006). Oncogenic rearrangements of the NTRK1/ NGF receptor. Cancer Lett 232, 90-98.
39. Fujimoto M, Kitazawa R, Maeda S, and Kitazawa S (2005). Methylation adjacent to negatively regulating AP-1 site reactivates TRK-A gene expression during cancer progression. Oncogene 24, 5108-5118.
40. Couturier J, Vincent-Salomon A, Nicolas A, Beuzeboc P, Mouret E, Zafrani B, and Sastre-Garau X (2000). Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol 13, 1238-1243.
41. Nabili V, Tan JW, Bhuta S, Sercarz JA, and Head CS (2007). Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck 29, 907-912.
42. Nashed M and Casasola RJ (2008). Biological therapy of salivary duct carcinoma. J Laryngol Otol 11, 1-3.
43. Prat A, Parera M, Reyes V, Peralta S, Cedrés S, Andreu J, Huguet P, and del Campo JM (2008). Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck 30, 680-683.
44. Abrams TJ, Lee LB, Murray LJ, Pryer NK, and Cherrington JM (2003). SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2, 471-478.
45. Chow LQ and Eckhardt SG (2007). Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25, 884-896.
46. Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A, and Siu LL (2005). Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 23, 585-590.
47. Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A, and Levitt M (2007). A phase II study of imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol 43, 33-36.